The Institute for Clinical and Economic Review (ICER) promotes itself as “the nation’s drug pricing watchdog.”  However, as documented in the first of a series of PRI reports, ICER’s cost-effectiveness analyses contain inappropriate methodologies and subjective judgments in determining the value of medicines.  In this podcast, PRI senior fellow Wayne Winegarden discusses why ICER’s reports contain biased, inaccurate assumptions.